secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inspire Medical Systems, Inc. (INSP)
CIK:        0001609550
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001609550-23-000049
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inspire Med: Q2 rev $151.1M (+65% YoY), raises FY2023 guidance to $600-610M
---------------------------------------------------------------------------

- Revenue of $151.1M, up 65% YoY; U.S. rev $144.7M (+65%), OUS $6.3M (+81%).
- Net loss improved to $12.0M from $14.5M; diluted EPS -$0.41 vs -$0.53.
- Full-year 2023 revenue guidance raised to $600-610M (prior $580-590M). Maintains gross margin 83-85%.
- FDA approved expanded AHI indication (up to 100 events/hr) and BMI labeling raise to 40; SleepSync programmer approved.
- Appointed Charisse Y. Sparks, M.D. as CMO, effective July 27; she resigned from board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609550/000160955023000049/0001609550-23-000049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609550/000160955023000049/insp-20230727.htm
  HTML page:      https://secwatch.observer/filing/0001609550-23-000049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer